Crystalys Therapeutics Taps Justin Thacker as CFO

Crystalys Therapeutics Inc., a clinical-stage biopharmaceutical company addressing the medical needs of people living with gout, has appointed Justin Thacker as Chief Financial Officer (CFO).

“We are incredibly excited to welcome Justin to our executive team,” remarked James M. Mackay, Ph.D., CEO and President of Crystalys. “Justin brings exceptional expertise and a proven track record of financial stewardship and strategic transactions. His experience strengthens our organization, and Justin’s contributions will play a critical role as we advance dotinurad through Phase 3 clinical trials and regulatory approval.”

About Justin Thacker

Thacker brings over 25 years of finance leadership experience, including over two decades in the life sciences sector spanning both private and public companies at the commercial and clinical stages. He has played key roles in driving multiple initial public offerings (IPOs), financings, product launches and M&A transactions.

Thacker has served as CFO for multiple biopharma organizations, including most recently at Capstan Therapeutics, where he helped guide the company through rapid growth and its acquisition by AbbVie, and Aristea Therapeutics, where he led core finance functions and IPO readiness. Previously, he held finance leadership roles at Design Therapeutics, Synthorx (acquired by Sanofi), ACADIA Pharmaceuticals, Auspex Pharmaceuticals (acquired by Teva Pharmaceuticals), and Cadence Pharmaceuticals (acquired by Mallinckrodt).

Thacker began his career with PricewaterhouseCoopers LLP and holds both a Master of Accountancy and a Bachelor of Science in Accounting and General Management from Kansas State University. He is a Certified Public Accountant in the State of Missouri.

“I’m thrilled to join Crystalys at such an exciting and meaningful stage in the company’s growth,” said Thacker. “The initiation of our Phase 3 trials, RUBY and TOPAZ, evaluating dotinurad as a potential best-in-class gout therapy, together with the momentum from our $205 million Series A financing, marks a transformative moment for the Company.”